Catalyst: XenoPort conducted an End-of-Phase 2 meeting with the FDA in which it received feedback that a proposed development program for XP21279, a novel prodrug of levodopa, could support a potential New Drug Application (NDA) submission under Section 505(b)(2) of…
Tag: money
3 Small Cap Bio-Pharmas With Trade Catalysts And Speculation Investment Potential
Zogenix (ZGNX) engages in the development and commercialization of products for the treatment of central nervous system disorders and pain. Its commercial product includes Sumavel DosePro (sumatriptan injection), a delivery system that offers needle-free subcutaneous administration of sumatriptan for the…
Huge Swing Trade Potential For Alexza Pharma With Two December Catalysts
Alexza Pharma (NASDAQ: ALXA) engages in the research, development, and commercialization of novel proprietary products for the acute treatment of central nervous system conditions. Its product candidates are based on a proprietary technology, the Staccato system, which vaporizes an excipient-free…
November 10 Biotech Update
This past week was a bit rough on the overall markets as on Tuesday, the markets seemed to bet on a Romney win, only to sell off the next day on news of an Obama win. The good news for…
Speculation In The Patent Litigation Segment: Seeking Out The Next Big Stock Movers.
There has been a lot of buzz lately about Vringo’s (VRNG) patent infringement lawsuit against Google (GOOG). Google’s ad placement system and its possible infringement of the Lang/Kosak Relevancy Filtering Technology with patents 420 and 664 are being called into…
